Tilt Biotherapeutics Signs an Agreement with Merck KGaA and Pfizer to Investigate the Dual Combination for Solid Tumors

 Tilt Biotherapeutics Signs an Agreement with Merck KGaA and Pfizer to Investigate the Dual Combination for Solid Tumors

Tilt Biotherapeutics Signs an Agreement with Merck KGaA and Pfizer to Investigate the Dual Combination for Solid Tumors

Shots:

  • Tilt initiates the collaboration with Merck KGaA & Pfizer to evaluate TILT-123 with avelumab in patients with solid tumors refractory to routine modalities
  • TILT-123 will evaluate for solid tumors in the US & Europe and preclinical results of the dual combination, TILT technology and anti-PDL1 agent demonstrated immune activation & efficacy
  • Bavencio (avelumab) is an anti-PD-L1 antibody act by blocking the interaction of PD-L1 with PD-1 receptors, co-develop & co-commercialize by Merck KGaA & Pfizer under the agreement signed in Nov’14. TILT-123 is an oncolytic adenovirus, replicates only in cancer cells producing immunostimulatory cytokines locally at the tumor site

Click here to read full press release/ article | Ref: Business Wire | Image: Owler

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post